nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—CYP1A2—Imiquimod—skin cancer	0.0969	0.153	CbGbCtD
Irbesartan—CYP2C8—Vismodegib—skin cancer	0.0868	0.137	CbGbCtD
Irbesartan—CYP2C9—Vismodegib—skin cancer	0.0605	0.0958	CbGbCtD
Irbesartan—CYP1A2—Vemurafenib—skin cancer	0.0531	0.084	CbGbCtD
Irbesartan—CYP3A4—Imiquimod—skin cancer	0.0508	0.0803	CbGbCtD
Irbesartan—CYP3A4—Temozolomide—skin cancer	0.0508	0.0803	CbGbCtD
Irbesartan—CYP2D6—Vemurafenib—skin cancer	0.0438	0.0692	CbGbCtD
Irbesartan—CYP1A2—Dacarbazine—skin cancer	0.0407	0.0644	CbGbCtD
Irbesartan—CYP3A4—Vismodegib—skin cancer	0.0352	0.0557	CbGbCtD
Irbesartan—CYP2C8—Fluorouracil—skin cancer	0.0308	0.0488	CbGbCtD
Irbesartan—CYP3A4—Vemurafenib—skin cancer	0.0278	0.044	CbGbCtD
Irbesartan—CYP1A2—Fluorouracil—skin cancer	0.0239	0.0377	CbGbCtD
Irbesartan—CYP2C9—Fluorouracil—skin cancer	0.0215	0.034	CbGbCtD
Irbesartan—CYP3A4—Docetaxel—skin cancer	0.00955	0.0151	CbGbCtD
Irbesartan—JUN—skin epidermis—skin cancer	0.006	0.0833	CbGeAlD
Irbesartan—JUN—nerve—skin cancer	0.00511	0.071	CbGeAlD
Irbesartan—JUN—endothelium—skin cancer	0.00435	0.0604	CbGeAlD
Irbesartan—JUN—blood vessel—skin cancer	0.00401	0.0557	CbGeAlD
Irbesartan—AGTR1—endothelium—skin cancer	0.00328	0.0455	CbGeAlD
Irbesartan—EDNRA—nipple—skin cancer	0.00318	0.0442	CbGeAlD
Irbesartan—AGTR1—blood vessel—skin cancer	0.00302	0.042	CbGeAlD
Irbesartan—JUN—nipple—skin cancer	0.0029	0.0403	CbGeAlD
Irbesartan—JUN—neck—skin cancer	0.00287	0.0399	CbGeAlD
Irbesartan—AGTR1—nipple—skin cancer	0.00218	0.0303	CbGeAlD
Irbesartan—AGTR1—neck—skin cancer	0.00216	0.03	CbGeAlD
Irbesartan—JUN—connective tissue—skin cancer	0.00206	0.0286	CbGeAlD
Irbesartan—JUN—epithelium—skin cancer	0.00195	0.0271	CbGeAlD
Irbesartan—JUN—skin of body—skin cancer	0.00186	0.0258	CbGeAlD
Irbesartan—EDNRA—mammalian vulva—skin cancer	0.00186	0.0258	CbGeAlD
Irbesartan—JUN—mammalian vulva—skin cancer	0.00169	0.0235	CbGeAlD
Irbesartan—AGTR1—connective tissue—skin cancer	0.00155	0.0215	CbGeAlD
Irbesartan—JUN—lymphoid tissue—skin cancer	0.0015	0.0209	CbGeAlD
Irbesartan—AGTR1—epithelium—skin cancer	0.00147	0.0204	CbGeAlD
Irbesartan—JUN—female reproductive system—skin cancer	0.00145	0.0202	CbGeAlD
Irbesartan—PTGS1—endothelium—skin cancer	0.00144	0.02	CbGeAlD
Irbesartan—PTGS1—blood vessel—skin cancer	0.00133	0.0185	CbGeAlD
Irbesartan—JUN—head—skin cancer	0.00121	0.0168	CbGeAlD
Irbesartan—AGTR1—lymphoid tissue—skin cancer	0.00113	0.0157	CbGeAlD
Irbesartan—CYP1A2—nipple—skin cancer	0.00111	0.0154	CbGeAlD
Irbesartan—AGTR1—female reproductive system—skin cancer	0.00109	0.0152	CbGeAlD
Irbesartan—PTGS1—nipple—skin cancer	0.000961	0.0133	CbGeAlD
Irbesartan—EDNRA—lymph node—skin cancer	0.00093	0.0129	CbGeAlD
Irbesartan—AGTR1—head—skin cancer	0.000913	0.0127	CbGeAlD
Irbesartan—JUN—lymph node—skin cancer	0.000849	0.0118	CbGeAlD
Irbesartan—PTGS1—connective tissue—skin cancer	0.000681	0.00946	CbGeAlD
Irbesartan—PTGS1—epithelium—skin cancer	0.000647	0.00898	CbGeAlD
Irbesartan—AGTR1—lymph node—skin cancer	0.000639	0.00888	CbGeAlD
Irbesartan—PTGS1—skin of body—skin cancer	0.000615	0.00854	CbGeAlD
Irbesartan—CYP2C8—female reproductive system—skin cancer	0.000592	0.00823	CbGeAlD
Irbesartan—PTGS1—mammalian vulva—skin cancer	0.000561	0.00779	CbGeAlD
Irbesartan—CYP2C9—female reproductive system—skin cancer	0.000526	0.00731	CbGeAlD
Irbesartan—PTGS1—female reproductive system—skin cancer	0.00048	0.00667	CbGeAlD
Irbesartan—PTGS1—head—skin cancer	0.000401	0.00558	CbGeAlD
Irbesartan—CYP3A4—female reproductive system—skin cancer	0.000401	0.00557	CbGeAlD
Irbesartan—CYP2D6—female reproductive system—skin cancer	0.000395	0.00549	CbGeAlD
Irbesartan—CYP2D6—head—skin cancer	0.00033	0.00458	CbGeAlD
Irbesartan—Malaise—Bleomycin—skin cancer	0.000313	0.00149	CcSEcCtD
Irbesartan—Cardiac disorder—Temozolomide—skin cancer	0.000312	0.00149	CcSEcCtD
Irbesartan—Flushing—Temozolomide—skin cancer	0.000312	0.00149	CcSEcCtD
Irbesartan—Leukopenia—Bleomycin—skin cancer	0.00031	0.00148	CcSEcCtD
Irbesartan—Rhinitis—Fluorouracil—skin cancer	0.00031	0.00148	CcSEcCtD
Irbesartan—Dizziness—Vemurafenib—skin cancer	0.000309	0.00148	CcSEcCtD
Irbesartan—Hypoaesthesia—Fluorouracil—skin cancer	0.000308	0.00147	CcSEcCtD
Irbesartan—Pharyngitis—Fluorouracil—skin cancer	0.000307	0.00147	CcSEcCtD
Irbesartan—Angiopathy—Temozolomide—skin cancer	0.000305	0.00146	CcSEcCtD
Irbesartan—Immune system disorder—Temozolomide—skin cancer	0.000303	0.00145	CcSEcCtD
Irbesartan—Mediastinal disorder—Temozolomide—skin cancer	0.000303	0.00145	CcSEcCtD
Irbesartan—Cough—Bleomycin—skin cancer	0.000302	0.00145	CcSEcCtD
Irbesartan—Chills—Temozolomide—skin cancer	0.000301	0.00144	CcSEcCtD
Irbesartan—Ill-defined disorder—Dactinomycin—skin cancer	0.0003	0.00143	CcSEcCtD
Irbesartan—Anaemia—Dactinomycin—skin cancer	0.000299	0.00143	CcSEcCtD
Irbesartan—Liver function test abnormal—Docetaxel—skin cancer	0.000298	0.00142	CcSEcCtD
Irbesartan—Vomiting—Vemurafenib—skin cancer	0.000297	0.00142	CcSEcCtD
Irbesartan—Myalgia—Bleomycin—skin cancer	0.000295	0.00141	CcSEcCtD
Irbesartan—Chest pain—Bleomycin—skin cancer	0.000295	0.00141	CcSEcCtD
Irbesartan—Orthostatic hypotension—Docetaxel—skin cancer	0.000295	0.00141	CcSEcCtD
Irbesartan—Abdominal pain upper—Docetaxel—skin cancer	0.000295	0.00141	CcSEcCtD
Irbesartan—Rash—Vemurafenib—skin cancer	0.000294	0.00141	CcSEcCtD
Irbesartan—Dermatitis—Vemurafenib—skin cancer	0.000294	0.00141	CcSEcCtD
Irbesartan—Hypersensitivity—Imiquimod—skin cancer	0.000293	0.0014	CcSEcCtD
Irbesartan—Headache—Vemurafenib—skin cancer	0.000292	0.0014	CcSEcCtD
Irbesartan—Erythema—Temozolomide—skin cancer	0.000292	0.0014	CcSEcCtD
Irbesartan—Malnutrition—Temozolomide—skin cancer	0.000292	0.0014	CcSEcCtD
Irbesartan—Breast disorder—Docetaxel—skin cancer	0.000292	0.00139	CcSEcCtD
Irbesartan—Discomfort—Bleomycin—skin cancer	0.000292	0.00139	CcSEcCtD
Irbesartan—Malaise—Dactinomycin—skin cancer	0.000292	0.00139	CcSEcCtD
Irbesartan—Cramp muscle—Docetaxel—skin cancer	0.000291	0.00139	CcSEcCtD
Irbesartan—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.000291	0.00139	CcSEcCtD
Irbesartan—Leukopenia—Dactinomycin—skin cancer	0.000289	0.00138	CcSEcCtD
Irbesartan—Nasopharyngitis—Docetaxel—skin cancer	0.000289	0.00138	CcSEcCtD
Irbesartan—Dysgeusia—Temozolomide—skin cancer	0.000286	0.00137	CcSEcCtD
Irbesartan—Asthenia—Imiquimod—skin cancer	0.000286	0.00137	CcSEcCtD
Irbesartan—Anaphylactic shock—Bleomycin—skin cancer	0.000283	0.00135	CcSEcCtD
Irbesartan—Oedema—Bleomycin—skin cancer	0.000283	0.00135	CcSEcCtD
Irbesartan—Pruritus—Imiquimod—skin cancer	0.000282	0.00135	CcSEcCtD
Irbesartan—PTGS1—lymph node—skin cancer	0.000281	0.0039	CbGeAlD
Irbesartan—Infection—Bleomycin—skin cancer	0.000281	0.00134	CcSEcCtD
Irbesartan—Dysphagia—Docetaxel—skin cancer	0.000279	0.00133	CcSEcCtD
Irbesartan—Nausea—Vemurafenib—skin cancer	0.000277	0.00133	CcSEcCtD
Irbesartan—Thrombocytopenia—Bleomycin—skin cancer	0.000277	0.00132	CcSEcCtD
Irbesartan—Arrhythmia—Fluorouracil—skin cancer	0.000276	0.00132	CcSEcCtD
Irbesartan—Vision blurred—Temozolomide—skin cancer	0.000276	0.00132	CcSEcCtD
Irbesartan—Myalgia—Dactinomycin—skin cancer	0.000275	0.00132	CcSEcCtD
Irbesartan—Tremor—Temozolomide—skin cancer	0.000274	0.00131	CcSEcCtD
Irbesartan—Diarrhoea—Imiquimod—skin cancer	0.000272	0.0013	CcSEcCtD
Irbesartan—Discomfort—Dactinomycin—skin cancer	0.000272	0.0013	CcSEcCtD
Irbesartan—Angina pectoris—Docetaxel—skin cancer	0.000272	0.0013	CcSEcCtD
Irbesartan—Ill-defined disorder—Temozolomide—skin cancer	0.000271	0.0013	CcSEcCtD
Irbesartan—Anaemia—Temozolomide—skin cancer	0.00027	0.00129	CcSEcCtD
Irbesartan—Anorexia—Bleomycin—skin cancer	0.00027	0.00129	CcSEcCtD
Irbesartan—Erythema—Fluorouracil—skin cancer	0.000269	0.00129	CcSEcCtD
Irbesartan—Agitation—Temozolomide—skin cancer	0.000269	0.00128	CcSEcCtD
Irbesartan—Angioedema—Temozolomide—skin cancer	0.000267	0.00128	CcSEcCtD
Irbesartan—Hypotension—Bleomycin—skin cancer	0.000264	0.00126	CcSEcCtD
Irbesartan—Oedema—Dactinomycin—skin cancer	0.000264	0.00126	CcSEcCtD
Irbesartan—Malaise—Temozolomide—skin cancer	0.000264	0.00126	CcSEcCtD
Irbesartan—Dizziness—Imiquimod—skin cancer	0.000263	0.00126	CcSEcCtD
Irbesartan—Vertigo—Temozolomide—skin cancer	0.000263	0.00126	CcSEcCtD
Irbesartan—Infection—Dactinomycin—skin cancer	0.000262	0.00125	CcSEcCtD
Irbesartan—Leukopenia—Temozolomide—skin cancer	0.000262	0.00125	CcSEcCtD
Irbesartan—Neutropenia—Docetaxel—skin cancer	0.000261	0.00125	CcSEcCtD
Irbesartan—Thrombocytopenia—Dactinomycin—skin cancer	0.000258	0.00123	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000258	0.00123	CcSEcCtD
Irbesartan—Cough—Temozolomide—skin cancer	0.000255	0.00122	CcSEcCtD
Irbesartan—Paraesthesia—Bleomycin—skin cancer	0.000254	0.00121	CcSEcCtD
Irbesartan—Weight increased—Docetaxel—skin cancer	0.000254	0.00121	CcSEcCtD
Irbesartan—Vision blurred—Fluorouracil—skin cancer	0.000254	0.00121	CcSEcCtD
Irbesartan—Vomiting—Imiquimod—skin cancer	0.000253	0.00121	CcSEcCtD
Irbesartan—Hypertension—Temozolomide—skin cancer	0.000252	0.00121	CcSEcCtD
Irbesartan—Dyspnoea—Bleomycin—skin cancer	0.000252	0.00121	CcSEcCtD
Irbesartan—Anorexia—Dactinomycin—skin cancer	0.000251	0.0012	CcSEcCtD
Irbesartan—Rash—Imiquimod—skin cancer	0.000251	0.0012	CcSEcCtD
Irbesartan—Dermatitis—Imiquimod—skin cancer	0.000251	0.0012	CcSEcCtD
Irbesartan—Pneumonia—Docetaxel—skin cancer	0.00025	0.0012	CcSEcCtD
Irbesartan—Headache—Imiquimod—skin cancer	0.000249	0.00119	CcSEcCtD
Irbesartan—Anaemia—Fluorouracil—skin cancer	0.000249	0.00119	CcSEcCtD
Irbesartan—Myalgia—Temozolomide—skin cancer	0.000249	0.00119	CcSEcCtD
Irbesartan—Arthralgia—Temozolomide—skin cancer	0.000249	0.00119	CcSEcCtD
Irbesartan—Anxiety—Temozolomide—skin cancer	0.000248	0.00119	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000247	0.00118	CcSEcCtD
Irbesartan—Discomfort—Temozolomide—skin cancer	0.000246	0.00118	CcSEcCtD
Irbesartan—Decreased appetite—Bleomycin—skin cancer	0.000246	0.00118	CcSEcCtD
Irbesartan—Acute coronary syndrome—Docetaxel—skin cancer	0.000245	0.00117	CcSEcCtD
Irbesartan—Renal failure—Docetaxel—skin cancer	0.000245	0.00117	CcSEcCtD
Irbesartan—Myocardial infarction—Docetaxel—skin cancer	0.000244	0.00117	CcSEcCtD
Irbesartan—Dry mouth—Temozolomide—skin cancer	0.000243	0.00116	CcSEcCtD
Irbesartan—Jaundice—Docetaxel—skin cancer	0.000243	0.00116	CcSEcCtD
Irbesartan—Pain—Bleomycin—skin cancer	0.000242	0.00116	CcSEcCtD
Irbesartan—Conjunctivitis—Docetaxel—skin cancer	0.000242	0.00116	CcSEcCtD
Irbesartan—Leukopenia—Fluorouracil—skin cancer	0.000241	0.00115	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.00024	0.00115	CcSEcCtD
Irbesartan—Anaphylactic shock—Temozolomide—skin cancer	0.000239	0.00114	CcSEcCtD
Irbesartan—Oedema—Temozolomide—skin cancer	0.000239	0.00114	CcSEcCtD
Irbesartan—Infection—Temozolomide—skin cancer	0.000237	0.00113	CcSEcCtD
Irbesartan—Nausea—Imiquimod—skin cancer	0.000237	0.00113	CcSEcCtD
Irbesartan—Hepatobiliary disease—Docetaxel—skin cancer	0.000235	0.00112	CcSEcCtD
Irbesartan—Epistaxis—Docetaxel—skin cancer	0.000235	0.00112	CcSEcCtD
Irbesartan—Nervous system disorder—Temozolomide—skin cancer	0.000234	0.00112	CcSEcCtD
Irbesartan—Thrombocytopenia—Temozolomide—skin cancer	0.000234	0.00112	CcSEcCtD
Irbesartan—Feeling abnormal—Bleomycin—skin cancer	0.000233	0.00111	CcSEcCtD
Irbesartan—Agranulocytosis—Docetaxel—skin cancer	0.000232	0.00111	CcSEcCtD
Irbesartan—Skin disorder—Temozolomide—skin cancer	0.000232	0.00111	CcSEcCtD
Irbesartan—Hyperhidrosis—Temozolomide—skin cancer	0.000231	0.0011	CcSEcCtD
Irbesartan—Chest pain—Fluorouracil—skin cancer	0.000229	0.0011	CcSEcCtD
Irbesartan—Myalgia—Fluorouracil—skin cancer	0.000229	0.0011	CcSEcCtD
Irbesartan—Decreased appetite—Dactinomycin—skin cancer	0.000229	0.0011	CcSEcCtD
Irbesartan—Fatigue—Dactinomycin—skin cancer	0.000227	0.00109	CcSEcCtD
Irbesartan—Anorexia—Temozolomide—skin cancer	0.000227	0.00109	CcSEcCtD
Irbesartan—Discomfort—Fluorouracil—skin cancer	0.000227	0.00108	CcSEcCtD
Irbesartan—Pain—Dactinomycin—skin cancer	0.000226	0.00108	CcSEcCtD
Irbesartan—Urticaria—Bleomycin—skin cancer	0.000225	0.00107	CcSEcCtD
Irbesartan—Rhinitis—Docetaxel—skin cancer	0.000224	0.00107	CcSEcCtD
Irbesartan—Body temperature increased—Bleomycin—skin cancer	0.000224	0.00107	CcSEcCtD
Irbesartan—Hepatitis—Docetaxel—skin cancer	0.000223	0.00107	CcSEcCtD
Irbesartan—Hypoaesthesia—Docetaxel—skin cancer	0.000222	0.00106	CcSEcCtD
Irbesartan—Pharyngitis—Docetaxel—skin cancer	0.000222	0.00106	CcSEcCtD
Irbesartan—Urinary tract disorder—Docetaxel—skin cancer	0.000221	0.00105	CcSEcCtD
Irbesartan—Oedema peripheral—Docetaxel—skin cancer	0.00022	0.00105	CcSEcCtD
Irbesartan—Anaphylactic shock—Fluorouracil—skin cancer	0.00022	0.00105	CcSEcCtD
Irbesartan—Oedema—Fluorouracil—skin cancer	0.00022	0.00105	CcSEcCtD
Irbesartan—Connective tissue disorder—Docetaxel—skin cancer	0.000219	0.00105	CcSEcCtD
Irbesartan—Urethral disorder—Docetaxel—skin cancer	0.000219	0.00105	CcSEcCtD
Irbesartan—Infection—Fluorouracil—skin cancer	0.000218	0.00104	CcSEcCtD
Irbesartan—Feeling abnormal—Dactinomycin—skin cancer	0.000217	0.00104	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000217	0.00104	CcSEcCtD
Irbesartan—Gastrointestinal pain—Dactinomycin—skin cancer	0.000216	0.00103	CcSEcCtD
Irbesartan—Nervous system disorder—Fluorouracil—skin cancer	0.000216	0.00103	CcSEcCtD
Irbesartan—Thrombocytopenia—Fluorouracil—skin cancer	0.000215	0.00103	CcSEcCtD
Irbesartan—Visual impairment—Docetaxel—skin cancer	0.000215	0.00103	CcSEcCtD
Irbesartan—Tachycardia—Fluorouracil—skin cancer	0.000215	0.00103	CcSEcCtD
Irbesartan—Paraesthesia—Temozolomide—skin cancer	0.000214	0.00102	CcSEcCtD
Irbesartan—Dyspnoea—Temozolomide—skin cancer	0.000213	0.00102	CcSEcCtD
Irbesartan—Somnolence—Temozolomide—skin cancer	0.000212	0.00101	CcSEcCtD
Irbesartan—Dyspepsia—Temozolomide—skin cancer	0.00021	0.001	CcSEcCtD
Irbesartan—Anorexia—Fluorouracil—skin cancer	0.00021	0.001	CcSEcCtD
Irbesartan—Abdominal pain—Dactinomycin—skin cancer	0.000209	0.000997	CcSEcCtD
Irbesartan—Body temperature increased—Dactinomycin—skin cancer	0.000209	0.000997	CcSEcCtD
Irbesartan—Hypersensitivity—Bleomycin—skin cancer	0.000208	0.000996	CcSEcCtD
Irbesartan—Decreased appetite—Temozolomide—skin cancer	0.000207	0.000991	CcSEcCtD
Irbesartan—Cardiac disorder—Docetaxel—skin cancer	0.000207	0.000991	CcSEcCtD
Irbesartan—Flushing—Docetaxel—skin cancer	0.000207	0.000991	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Temozolomide—skin cancer	0.000206	0.000984	CcSEcCtD
Irbesartan—Fatigue—Temozolomide—skin cancer	0.000206	0.000983	CcSEcCtD
Irbesartan—Hypotension—Fluorouracil—skin cancer	0.000205	0.000982	CcSEcCtD
Irbesartan—Constipation—Temozolomide—skin cancer	0.000204	0.000975	CcSEcCtD
Irbesartan—Pain—Temozolomide—skin cancer	0.000204	0.000975	CcSEcCtD
Irbesartan—Asthenia—Bleomycin—skin cancer	0.000203	0.00097	CcSEcCtD
Irbesartan—Angiopathy—Docetaxel—skin cancer	0.000203	0.000968	CcSEcCtD
Irbesartan—Immune system disorder—Docetaxel—skin cancer	0.000202	0.000964	CcSEcCtD
Irbesartan—Mediastinal disorder—Docetaxel—skin cancer	0.000201	0.000962	CcSEcCtD
Irbesartan—Chills—Docetaxel—skin cancer	0.0002	0.000958	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.0002	0.000957	CcSEcCtD
Irbesartan—Pruritus—Bleomycin—skin cancer	0.0002	0.000956	CcSEcCtD
Irbesartan—Arrhythmia—Docetaxel—skin cancer	0.0002	0.000954	CcSEcCtD
Irbesartan—Paraesthesia—Fluorouracil—skin cancer	0.000197	0.000943	CcSEcCtD
Irbesartan—Feeling abnormal—Temozolomide—skin cancer	0.000197	0.00094	CcSEcCtD
Irbesartan—Dyspnoea—Fluorouracil—skin cancer	0.000196	0.000937	CcSEcCtD
Irbesartan—Somnolence—Fluorouracil—skin cancer	0.000195	0.000934	CcSEcCtD
Irbesartan—Gastrointestinal pain—Temozolomide—skin cancer	0.000195	0.000932	CcSEcCtD
Irbesartan—Erythema—Docetaxel—skin cancer	0.000194	0.000929	CcSEcCtD
Irbesartan—Malnutrition—Docetaxel—skin cancer	0.000194	0.000929	CcSEcCtD
Irbesartan—Hypersensitivity—Dactinomycin—skin cancer	0.000194	0.000929	CcSEcCtD
Irbesartan—Dyspepsia—Fluorouracil—skin cancer	0.000194	0.000925	CcSEcCtD
Irbesartan—Decreased appetite—Fluorouracil—skin cancer	0.000191	0.000913	CcSEcCtD
Irbesartan—Dysgeusia—Docetaxel—skin cancer	0.00019	0.00091	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Fluorouracil—skin cancer	0.00019	0.000907	CcSEcCtD
Irbesartan—Urticaria—Temozolomide—skin cancer	0.00019	0.000906	CcSEcCtD
Irbesartan—Asthenia—Dactinomycin—skin cancer	0.000189	0.000905	CcSEcCtD
Irbesartan—Abdominal pain—Temozolomide—skin cancer	0.000189	0.000901	CcSEcCtD
Irbesartan—Body temperature increased—Temozolomide—skin cancer	0.000189	0.000901	CcSEcCtD
Irbesartan—Pain—Fluorouracil—skin cancer	0.000188	0.000898	CcSEcCtD
Irbesartan—Muscle spasms—Docetaxel—skin cancer	0.000187	0.000893	CcSEcCtD
Irbesartan—JUN—FCERI mediated MAPK activation—IL6—skin cancer	0.000184	0.00213	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—RHOU—skin cancer	0.000182	0.0021	CbGpPWpGaD
Irbesartan—Feeling abnormal—Fluorouracil—skin cancer	0.000181	0.000866	CcSEcCtD
Irbesartan—Diarrhoea—Dactinomycin—skin cancer	0.000181	0.000863	CcSEcCtD
Irbesartan—Vomiting—Bleomycin—skin cancer	0.00018	0.00086	CcSEcCtD
Irbesartan—Anaemia—Docetaxel—skin cancer	0.00018	0.000859	CcSEcCtD
Irbesartan—Rash—Bleomycin—skin cancer	0.000178	0.000852	CcSEcCtD
Irbesartan—Dermatitis—Bleomycin—skin cancer	0.000178	0.000852	CcSEcCtD
Irbesartan—JUN—PDGFR-beta signaling pathway—BRAF—skin cancer	0.000178	0.00206	CbGpPWpGaD
Irbesartan—JUN—Senescence and Autophagy in Cancer—CDKN2A—skin cancer	0.000177	0.00204	CbGpPWpGaD
Irbesartan—JUN—Senescence-Associated Secretory Phenotype (SASP)—CDKN2A—skin cancer	0.000177	0.00204	CbGpPWpGaD
Irbesartan—Hypersensitivity—Temozolomide—skin cancer	0.000176	0.00084	CcSEcCtD
Irbesartan—Urticaria—Fluorouracil—skin cancer	0.000175	0.000835	CcSEcCtD
Irbesartan—Syncope—Docetaxel—skin cancer	0.000174	0.000833	CcSEcCtD
Irbesartan—Leukopenia—Docetaxel—skin cancer	0.000174	0.000832	CcSEcCtD
Irbesartan—Body temperature increased—Fluorouracil—skin cancer	0.000174	0.000831	CcSEcCtD
Irbesartan—JUN—IL-3 Signaling Pathway—HRAS—skin cancer	0.000173	0.002	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—CDK4—skin cancer	0.000173	0.002	CbGpPWpGaD
Irbesartan—JUN—Copper homeostasis—TP53—skin cancer	0.000173	0.002	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—CDKN2A—skin cancer	0.000172	0.00198	CbGpPWpGaD
Irbesartan—JUN—IL6-mediated signaling events—IL6—skin cancer	0.000171	0.00198	CbGpPWpGaD
Irbesartan—Asthenia—Temozolomide—skin cancer	0.000171	0.000818	CcSEcCtD
Irbesartan—Loss of consciousness—Docetaxel—skin cancer	0.000171	0.000817	CcSEcCtD
Irbesartan—Cough—Docetaxel—skin cancer	0.00017	0.000811	CcSEcCtD
Irbesartan—Pruritus—Temozolomide—skin cancer	0.000169	0.000807	CcSEcCtD
Irbesartan—Nausea—Bleomycin—skin cancer	0.000168	0.000803	CcSEcCtD
Irbesartan—Hypertension—Docetaxel—skin cancer	0.000168	0.000802	CcSEcCtD
Irbesartan—Vomiting—Dactinomycin—skin cancer	0.000168	0.000802	CcSEcCtD
Irbesartan—JUN—ErbB Signaling Pathway—TP53—skin cancer	0.000167	0.00194	CbGpPWpGaD
Irbesartan—Rash—Dactinomycin—skin cancer	0.000166	0.000795	CcSEcCtD
Irbesartan—Arthralgia—Docetaxel—skin cancer	0.000166	0.000791	CcSEcCtD
Irbesartan—Chest pain—Docetaxel—skin cancer	0.000166	0.000791	CcSEcCtD
Irbesartan—Myalgia—Docetaxel—skin cancer	0.000166	0.000791	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000164	0.000786	CcSEcCtD
Irbesartan—Diarrhoea—Temozolomide—skin cancer	0.000163	0.00078	CcSEcCtD
Irbesartan—Hypersensitivity—Fluorouracil—skin cancer	0.000162	0.000774	CcSEcCtD
Irbesartan—Dry mouth—Docetaxel—skin cancer	0.000162	0.000774	CcSEcCtD
Irbesartan—JUN—Downstream signaling in naïve CD8+ T cells—KRAS—skin cancer	0.000161	0.00186	CbGpPWpGaD
Irbesartan—JUN—ErbB Signaling Pathway—HRAS—skin cancer	0.00016	0.00185	CbGpPWpGaD
Irbesartan—JUN—IL2-mediated signaling events—HRAS—skin cancer	0.00016	0.00185	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Receptor Signaling—HRAS—skin cancer	0.00016	0.00185	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—MC1R—skin cancer	0.00016	0.00185	CbGpPWpGaD
Irbesartan—JUN—Oxidative Stress Induced Senescence—CDKN2A—skin cancer	0.00016	0.00185	CbGpPWpGaD
Irbesartan—Anaphylactic shock—Docetaxel—skin cancer	0.000159	0.000758	CcSEcCtD
Irbesartan—Oedema—Docetaxel—skin cancer	0.000159	0.000758	CcSEcCtD
Irbesartan—Dizziness—Temozolomide—skin cancer	0.000158	0.000754	CcSEcCtD
Irbesartan—Infection—Docetaxel—skin cancer	0.000158	0.000753	CcSEcCtD
Irbesartan—Nausea—Dactinomycin—skin cancer	0.000157	0.000749	CcSEcCtD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.000156	0.00181	CbGpPWpGaD
Irbesartan—Shock—Docetaxel—skin cancer	0.000156	0.000746	CcSEcCtD
Irbesartan—Nervous system disorder—Docetaxel—skin cancer	0.000156	0.000744	CcSEcCtD
Irbesartan—Pruritus—Fluorouracil—skin cancer	0.000156	0.000743	CcSEcCtD
Irbesartan—Thrombocytopenia—Docetaxel—skin cancer	0.000155	0.000742	CcSEcCtD
Irbesartan—Tachycardia—Docetaxel—skin cancer	0.000155	0.00074	CcSEcCtD
Irbesartan—Skin disorder—Docetaxel—skin cancer	0.000154	0.000737	CcSEcCtD
Irbesartan—JUN—Integrated Breast Cancer Pathway—BRAF—skin cancer	0.000153	0.00177	CbGpPWpGaD
Irbesartan—Vomiting—Temozolomide—skin cancer	0.000152	0.000725	CcSEcCtD
Irbesartan—EDNRA—Signaling Pathways—PTCH2—skin cancer	0.000151	0.00175	CbGpPWpGaD
Irbesartan—Anorexia—Docetaxel—skin cancer	0.000151	0.000723	CcSEcCtD
Irbesartan—Rash—Temozolomide—skin cancer	0.00015	0.000719	CcSEcCtD
Irbesartan—Diarrhoea—Fluorouracil—skin cancer	0.00015	0.000719	CcSEcCtD
Irbesartan—Dermatitis—Temozolomide—skin cancer	0.00015	0.000718	CcSEcCtD
Irbesartan—Headache—Temozolomide—skin cancer	0.000149	0.000714	CcSEcCtD
Irbesartan—JUN—MAP kinase activation in TLR cascade—IL6—skin cancer	0.000149	0.00172	CbGpPWpGaD
Irbesartan—Hypotension—Docetaxel—skin cancer	0.000148	0.000709	CcSEcCtD
Irbesartan—JUN—Cellular Senescence—CDK4—skin cancer	0.000146	0.00169	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—MC1R—skin cancer	0.000145	0.00168	CbGpPWpGaD
Irbesartan—Dizziness—Fluorouracil—skin cancer	0.000145	0.000695	CcSEcCtD
Irbesartan—JUN—Fc-epsilon receptor I signaling in mast cells—HRAS—skin cancer	0.000145	0.00168	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—BRAF—skin cancer	0.000145	0.00167	CbGpPWpGaD
Irbesartan—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000145	0.000691	CcSEcCtD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	0.000143	0.00166	CbGpPWpGaD
Irbesartan—JUN—TNF alpha Signaling Pathway—NRAS—skin cancer	0.000143	0.00165	CbGpPWpGaD
Irbesartan—JUN—ATF-2 transcription factor network—IL6—skin cancer	0.000143	0.00165	CbGpPWpGaD
Irbesartan—Paraesthesia—Docetaxel—skin cancer	0.000142	0.000681	CcSEcCtD
Irbesartan—Nausea—Temozolomide—skin cancer	0.000142	0.000677	CcSEcCtD
Irbesartan—JUN—Endothelins—HRAS—skin cancer	0.000142	0.00164	CbGpPWpGaD
Irbesartan—Dyspnoea—Docetaxel—skin cancer	0.000141	0.000676	CcSEcCtD
Irbesartan—Somnolence—Docetaxel—skin cancer	0.000141	0.000674	CcSEcCtD
Irbesartan—JUN—MAPK Signaling Pathway—BRAF—skin cancer	0.000141	0.00162	CbGpPWpGaD
Irbesartan—JUN—LPA receptor mediated events—HRAS—skin cancer	0.00014	0.00162	CbGpPWpGaD
Irbesartan—Vomiting—Fluorouracil—skin cancer	0.00014	0.000668	CcSEcCtD
Irbesartan—Dyspepsia—Docetaxel—skin cancer	0.00014	0.000668	CcSEcCtD
Irbesartan—Rash—Fluorouracil—skin cancer	0.000139	0.000662	CcSEcCtD
Irbesartan—Dermatitis—Fluorouracil—skin cancer	0.000138	0.000662	CcSEcCtD
Irbesartan—Decreased appetite—Docetaxel—skin cancer	0.000138	0.000659	CcSEcCtD
Irbesartan—Headache—Fluorouracil—skin cancer	0.000138	0.000658	CcSEcCtD
Irbesartan—JUN—Circadian rythm related genes—CDK4—skin cancer	0.000138	0.00159	CbGpPWpGaD
Irbesartan—Gastrointestinal disorder—Docetaxel—skin cancer	0.000137	0.000655	CcSEcCtD
Irbesartan—Fatigue—Docetaxel—skin cancer	0.000137	0.000654	CcSEcCtD
Irbesartan—JUN—TSH signaling pathway—HRAS—skin cancer	0.000136	0.00158	CbGpPWpGaD
Irbesartan—JUN—Downstream signaling in naïve CD8+ T cells—HRAS—skin cancer	0.000136	0.00158	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—TP53—skin cancer	0.000136	0.00157	CbGpPWpGaD
Irbesartan—Pain—Docetaxel—skin cancer	0.000136	0.000648	CcSEcCtD
Irbesartan—Constipation—Docetaxel—skin cancer	0.000136	0.000648	CcSEcCtD
Irbesartan—CYP2C8—Arachidonic acid metabolism—PTGS2—skin cancer	0.000135	0.00156	CbGpPWpGaD
Irbesartan—JUN—BCR signaling pathway—HRAS—skin cancer	0.000135	0.00156	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—PTGER4—skin cancer	0.000134	0.00155	CbGpPWpGaD
Irbesartan—PTGS1—Selenium Micronutrient Network—PTGS2—skin cancer	0.000133	0.00154	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—SHH—skin cancer	0.000132	0.00153	CbGpPWpGaD
Irbesartan—Feeling abnormal—Docetaxel—skin cancer	0.000131	0.000625	CcSEcCtD
Irbesartan—Nausea—Fluorouracil—skin cancer	0.000131	0.000624	CcSEcCtD
Irbesartan—JUN—CDC42 signaling events—HRAS—skin cancer	0.00013	0.0015	CbGpPWpGaD
Irbesartan—Gastrointestinal pain—Docetaxel—skin cancer	0.00013	0.00062	CcSEcCtD
Irbesartan—JUN—ErbB1 downstream signaling—NRAS—skin cancer	0.000129	0.00149	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—BRAF—skin cancer	0.000127	0.00147	CbGpPWpGaD
Irbesartan—Abdominal pain—Docetaxel—skin cancer	0.000125	0.000599	CcSEcCtD
Irbesartan—Body temperature increased—Docetaxel—skin cancer	0.000125	0.000599	CcSEcCtD
Irbesartan—EDNRA—Signaling by GPCR—PTCH1—skin cancer	0.000125	0.00145	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—SMO—skin cancer	0.000125	0.00145	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—NRAS—skin cancer	0.000125	0.00144	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—IL6—skin cancer	0.000125	0.00144	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PLIN2—skin cancer	0.000124	0.00143	CbGpPWpGaD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	0.000124	0.00143	CbGpPWpGaD
Irbesartan—JUN—TNF alpha Signaling Pathway—KRAS—skin cancer	0.000123	0.00142	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—PTGER4—skin cancer	0.000122	0.00141	CbGpPWpGaD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—TP53—skin cancer	0.00012	0.00139	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PTCH2—skin cancer	0.000119	0.00137	CbGpPWpGaD
Irbesartan—JUN—TRAF6 Mediated Induction of proinflammatory cytokines—IL6—skin cancer	0.000118	0.00136	CbGpPWpGaD
Irbesartan—JUN—Apoptosis—TP53—skin cancer	0.000118	0.00136	CbGpPWpGaD
Irbesartan—JUN—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—HRAS—skin cancer	0.000117	0.00135	CbGpPWpGaD
Irbesartan—Hypersensitivity—Docetaxel—skin cancer	0.000117	0.000559	CcSEcCtD
Irbesartan—EDNRA—Signaling Pathways—GLI2—skin cancer	0.000115	0.00133	CbGpPWpGaD
Irbesartan—Asthenia—Docetaxel—skin cancer	0.000114	0.000544	CcSEcCtD
Irbesartan—Pruritus—Docetaxel—skin cancer	0.000112	0.000537	CcSEcCtD
Irbesartan—JUN—Immune System—TLR7—skin cancer	0.000112	0.00129	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—CDKN2A—skin cancer	0.000112	0.00129	CbGpPWpGaD
Irbesartan—JUN—PDGFR-beta signaling pathway—NRAS—skin cancer	0.000112	0.00129	CbGpPWpGaD
Irbesartan—JUN—ErbB1 downstream signaling—KRAS—skin cancer	0.000111	0.00128	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—CDK4—skin cancer	0.000111	0.00128	CbGpPWpGaD
Irbesartan—JUN—Apoptosis Modulation and Signaling—TP53—skin cancer	0.00011	0.00128	CbGpPWpGaD
Irbesartan—CYP2C9—Arachidonic acid metabolism—PTGS2—skin cancer	0.00011	0.00127	CbGpPWpGaD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—IL6—skin cancer	0.00011	0.00127	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MC1R—skin cancer	0.000109	0.00127	CbGpPWpGaD
Irbesartan—Diarrhoea—Docetaxel—skin cancer	0.000109	0.000519	CcSEcCtD
Irbesartan—EDNRA—Signaling Pathways—GLI1—skin cancer	0.000108	0.00125	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—KRAS—skin cancer	0.000107	0.00124	CbGpPWpGaD
Irbesartan—JUN—MyD88 cascade initiated on plasma membrane—IL6—skin cancer	0.000107	0.00123	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—HRAS—skin cancer	0.000106	0.00123	CbGpPWpGaD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	0.000106	0.00123	CbGpPWpGaD
Irbesartan—JUN—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—IL6—skin cancer	0.000106	0.00122	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—PTGER4—skin cancer	0.000105	0.00122	CbGpPWpGaD
Irbesartan—Dizziness—Docetaxel—skin cancer	0.000105	0.000501	CcSEcCtD
Irbesartan—JUN—TNF alpha Signaling Pathway—HRAS—skin cancer	0.000105	0.00121	CbGpPWpGaD
Irbesartan—JUN—MyD88 dependent cascade initiated on endosome—IL6—skin cancer	0.000104	0.0012	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—SHH—skin cancer	0.000104	0.0012	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	0.000102	0.00118	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—SUFU—skin cancer	0.000102	0.00118	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—IL6—skin cancer	0.000102	0.00118	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.000101	0.00117	CbGpPWpGaD
Irbesartan—Vomiting—Docetaxel—skin cancer	0.000101	0.000482	CcSEcCtD
Irbesartan—JUN—Wnt Signaling Pathway and Pluripotency—TP53—skin cancer	0.000101	0.00116	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—skin cancer	0.0001	0.00116	CbGpPWpGaD
Irbesartan—JUN—B Cell Receptor Signaling Pathway—HRAS—skin cancer	0.0001	0.00116	CbGpPWpGaD
Irbesartan—JUN—TNF alpha Signaling Pathway—IL6—skin cancer	0.0001	0.00116	CbGpPWpGaD
Irbesartan—JUN—Toll Like Receptor 9 (TLR9) Cascade—IL6—skin cancer	0.0001	0.00116	CbGpPWpGaD
Irbesartan—Rash—Docetaxel—skin cancer	0.0001	0.000478	CcSEcCtD
Irbesartan—Dermatitis—Docetaxel—skin cancer	0.0001	0.000478	CcSEcCtD
Irbesartan—UGT1A3—Metabolism—CSPG4—skin cancer	9.97e-05	0.00115	CbGpPWpGaD
Irbesartan—Headache—Docetaxel—skin cancer	9.94e-05	0.000475	CcSEcCtD
Irbesartan—JUN—Innate Immune System—FOXO4—skin cancer	9.9e-05	0.00114	CbGpPWpGaD
Irbesartan—JUN—MyD88:Mal cascade initiated on plasma membrane—IL6—skin cancer	9.84e-05	0.00114	CbGpPWpGaD
Irbesartan—JUN—Senescence and Autophagy in Cancer—TP53—skin cancer	9.84e-05	0.00114	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—PTCH1—skin cancer	9.82e-05	0.00114	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—SMO—skin cancer	9.82e-05	0.00114	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	9.7e-05	0.00112	CbGpPWpGaD
Irbesartan—JUN—PDGFR-beta signaling pathway—KRAS—skin cancer	9.63e-05	0.00111	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—PTGER4—skin cancer	9.56e-05	0.00111	CbGpPWpGaD
Irbesartan—JUN—Signaling by NOTCH—TP53—skin cancer	9.55e-05	0.0011	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—TP53—skin cancer	9.55e-05	0.0011	CbGpPWpGaD
Irbesartan—JUN—MyD88-independent cascade—IL6—skin cancer	9.44e-05	0.00109	CbGpPWpGaD
Irbesartan—Nausea—Docetaxel—skin cancer	9.43e-05	0.00045	CcSEcCtD
Irbesartan—JUN—Senescence and Autophagy in Cancer—HRAS—skin cancer	9.41e-05	0.00109	CbGpPWpGaD
Irbesartan—JUN—ErbB1 downstream signaling—HRAS—skin cancer	9.41e-05	0.00109	CbGpPWpGaD
Irbesartan—CYP1A2—Arachidonic acid metabolism—PTGS2—skin cancer	9.39e-05	0.00109	CbGpPWpGaD
Irbesartan—JUN—Toll-like Receptor Signaling Pathway—IL6—skin cancer	9.22e-05	0.00107	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—HRAS—skin cancer	9.13e-05	0.00106	CbGpPWpGaD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	9.05e-05	0.00105	CbGpPWpGaD
Irbesartan—JUN—Senescence and Autophagy in Cancer—IL6—skin cancer	9.01e-05	0.00104	CbGpPWpGaD
Irbesartan—JUN—Senescence-Associated Secretory Phenotype (SASP)—IL6—skin cancer	9.01e-05	0.00104	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—GLI2—skin cancer	9.01e-05	0.00104	CbGpPWpGaD
Irbesartan—JUN—Oxidative Stress Induced Senescence—TP53—skin cancer	8.9e-05	0.00103	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PTCH2—skin cancer	8.88e-05	0.00103	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—NRAS—skin cancer	8.83e-05	0.00102	CbGpPWpGaD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	8.66e-05	0.001	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MC1R—skin cancer	8.59e-05	0.000993	CbGpPWpGaD
Irbesartan—JUN—Activated TLR4 signalling—IL6—skin cancer	8.49e-05	0.000982	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—NRAS—skin cancer	8.47e-05	0.000979	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—GLI1—skin cancer	8.47e-05	0.000979	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—CDKN2A—skin cancer	8.46e-05	0.000978	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	8.35e-05	0.000966	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—KRAS—skin cancer	8.28e-05	0.000957	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	8.23e-05	0.000951	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Signaling Pathway—TP53—skin cancer	8.19e-05	0.000947	CbGpPWpGaD
Irbesartan—JUN—PDGFR-beta signaling pathway—HRAS—skin cancer	8.18e-05	0.000946	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—SUFU—skin cancer	8.03e-05	0.000928	CbGpPWpGaD
Irbesartan—JUN—Toll Like Receptor 4 (TLR4) Cascade—IL6—skin cancer	7.99e-05	0.000923	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—KRAS—skin cancer	7.83e-05	0.000905	CbGpPWpGaD
Irbesartan—JUN—Direct p53 effectors—TP53—skin cancer	7.82e-05	0.000904	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—skin cancer	7.81e-05	0.000902	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—SHH—skin cancer	7.8e-05	0.000902	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—RASA1—skin cancer	7.75e-05	0.000896	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—KRAS—skin cancer	7.6e-05	0.000879	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—SMO—skin cancer	7.4e-05	0.000855	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PTCH1—skin cancer	7.4e-05	0.000855	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—TP53—skin cancer	7.36e-05	0.000851	CbGpPWpGaD
Irbesartan—JUN—BDNF signaling pathway—HRAS—skin cancer	7.31e-05	0.000845	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—KRAS—skin cancer	7.29e-05	0.000843	CbGpPWpGaD
Irbesartan—PTGS1—Selenium Micronutrient Network—IL6—skin cancer	7.24e-05	0.000837	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PTGER4—skin cancer	7.2e-05	0.000832	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—IL6—skin cancer	7.2e-05	0.000832	CbGpPWpGaD
Irbesartan—JUN—Toll-Like Receptors Cascades—IL6—skin cancer	7.11e-05	0.000822	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	7.1e-05	0.000821	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	7.03e-05	0.000813	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PLIN2—skin cancer	6.97e-05	0.000806	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	6.86e-05	0.000793	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	6.79e-05	0.000786	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—ENO2—skin cancer	6.78e-05	0.000784	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—TP53—skin cancer	6.76e-05	0.000781	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—GLI2—skin cancer	6.73e-05	0.000778	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—skin cancer	6.72e-05	0.000777	CbGpPWpGaD
Irbesartan—JUN—Insulin Signaling—HRAS—skin cancer	6.72e-05	0.000777	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—HRAS—skin cancer	6.65e-05	0.000769	CbGpPWpGaD
Irbesartan—JUN—Myometrial Relaxation and Contraction Pathways—IL6—skin cancer	6.6e-05	0.000762	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—IL6—skin cancer	6.56e-05	0.000759	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MC1R—skin cancer	6.42e-05	0.000742	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—FOXO4—skin cancer	6.36e-05	0.000735	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—GLI1—skin cancer	6.33e-05	0.000731	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—TP53—skin cancer	6.23e-05	0.00072	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—HRAS—skin cancer	6.2e-05	0.000716	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—SHH—skin cancer	6.12e-05	0.000708	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	6.1e-05	0.000705	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—RASA1—skin cancer	6.08e-05	0.000703	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SUFU—skin cancer	6e-05	0.000693	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	5.93e-05	0.000686	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—HRAS—skin cancer	5.86e-05	0.000677	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—TP53—skin cancer	5.85e-05	0.000677	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—SMO—skin cancer	5.8e-05	0.000671	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PTCH1—skin cancer	5.8e-05	0.000671	CbGpPWpGaD
Irbesartan—JUN—Immune System—FOXO4—skin cancer	5.77e-05	0.000667	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—skin cancer	5.71e-05	0.00066	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—IL6—skin cancer	5.7e-05	0.000659	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PTGER4—skin cancer	5.65e-05	0.000653	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CSPG4—skin cancer	5.62e-05	0.000649	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—IL6—skin cancer	5.36e-05	0.000619	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—FOXO4—skin cancer	4.99e-05	0.000577	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—TP53—skin cancer	4.71e-05	0.000544	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SHH—skin cancer	4.57e-05	0.000529	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—RASA1—skin cancer	4.54e-05	0.000525	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PLIN2—skin cancer	4.5e-05	0.00052	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SMO—skin cancer	4.34e-05	0.000501	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PTCH1—skin cancer	4.34e-05	0.000501	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—IL6—skin cancer	4.31e-05	0.000498	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TERT—skin cancer	4.25e-05	0.000491	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PTGER4—skin cancer	4.22e-05	0.000488	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—ERCC2—skin cancer	3.94e-05	0.000455	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ENO2—skin cancer	3.82e-05	0.000441	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—FOXO4—skin cancer	3.73e-05	0.000431	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PLIN2—skin cancer	3.7e-05	0.000427	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PLIN2—skin cancer	3.66e-05	0.000423	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CSPG4—skin cancer	3.63e-05	0.000419	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—NRAS—skin cancer	3.58e-05	0.000414	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—BRAF—skin cancer	3.36e-05	0.000389	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TERT—skin cancer	3.33e-05	0.000385	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—NRAS—skin cancer	3.29e-05	0.00038	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PLIN2—skin cancer	3.13e-05	0.000362	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—KRAS—skin cancer	3.08e-05	0.000356	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	2.99e-05	0.000345	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CSPG4—skin cancer	2.98e-05	0.000344	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CSPG4—skin cancer	2.95e-05	0.000341	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—KRAS—skin cancer	2.83e-05	0.000327	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—NRAS—skin cancer	2.81e-05	0.000325	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—BRAF—skin cancer	2.64e-05	0.000305	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—HRAS—skin cancer	2.62e-05	0.000303	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CSPG4—skin cancer	2.52e-05	0.000292	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—IL6—skin cancer	2.51e-05	0.00029	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TERT—skin cancer	2.49e-05	0.000288	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ENO2—skin cancer	2.47e-05	0.000285	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—KRAS—skin cancer	2.42e-05	0.000279	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PLIN2—skin cancer	2.42e-05	0.000279	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—HRAS—skin cancer	2.41e-05	0.000278	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PTGS2—skin cancer	2.36e-05	0.000273	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—IL6—skin cancer	2.3e-05	0.000266	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ERCC2—skin cancer	2.22e-05	0.000256	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—NRAS—skin cancer	2.11e-05	0.000244	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—HRAS—skin cancer	2.05e-05	0.000237	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ENO2—skin cancer	2.02e-05	0.000234	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ENO2—skin cancer	2.01e-05	0.000232	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—BRAF—skin cancer	1.97e-05	0.000228	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—IL6—skin cancer	1.97e-05	0.000227	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CSPG4—skin cancer	1.95e-05	0.000225	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.93e-05	0.000223	CbGpPWpGaD
Irbesartan—JUN—Immune System—NRAS—skin cancer	1.92e-05	0.000222	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—KRAS—skin cancer	1.82e-05	0.00021	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ENO2—skin cancer	1.72e-05	0.000198	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—NRAS—skin cancer	1.66e-05	0.000192	CbGpPWpGaD
Irbesartan—JUN—Immune System—KRAS—skin cancer	1.65e-05	0.000191	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TP53—skin cancer	1.62e-05	0.000187	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.57e-05	0.000181	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—HRAS—skin cancer	1.55e-05	0.000179	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IL6—skin cancer	1.48e-05	0.000171	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ERCC2—skin cancer	1.43e-05	0.000166	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—KRAS—skin cancer	1.43e-05	0.000165	CbGpPWpGaD
Irbesartan—JUN—Immune System—HRAS—skin cancer	1.4e-05	0.000162	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL6—skin cancer	1.34e-05	0.000155	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.34e-05	0.000155	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTGS2—skin cancer	1.33e-05	0.000154	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ENO2—skin cancer	1.32e-05	0.000153	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TP53—skin cancer	1.27e-05	0.000147	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NRAS—skin cancer	1.24e-05	0.000143	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—HRAS—skin cancer	1.21e-05	0.00014	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ERCC2—skin cancer	1.18e-05	0.000136	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ERCC2—skin cancer	1.17e-05	0.000135	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL6—skin cancer	1.16e-05	0.000134	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KRAS—skin cancer	1.07e-05	0.000123	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ERCC2—skin cancer	9.96e-06	0.000115	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TP53—skin cancer	9.48e-06	0.00011	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—HRAS—skin cancer	9.07e-06	0.000105	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL6—skin cancer	8.68e-06	0.0001	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTGS2—skin cancer	8.59e-06	9.93e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ERCC2—skin cancer	7.69e-06	8.89e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTGS2—skin cancer	7.05e-06	8.15e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTGS2—skin cancer	6.99e-06	8.08e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTGS2—skin cancer	5.97e-06	6.91e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTGS2—skin cancer	4.61e-06	5.33e-05	CbGpPWpGaD
